Sangamo Therapeutics Analyst Ratings
BenzingaMar 19 18:24
Sangamo Therapeutics Analyst Ratings
BenzingaMar 14 23:26
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
BenzingaMar 14 23:28
Sangamo Therapeutics Analyst Ratings
BenzingaMar 14 00:47
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
BenzingaFeb 13 01:48
Sangamo Therapeutics Analyst Ratings
BenzingaFeb 13 01:46
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
BenzingaFeb 6 21:49
Sangamo Therapeutics Analyst Ratings
BenzingaFeb 6 21:46
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
BenzingaJan 19 19:59
Sangamo Therapeutics Analyst Ratings
BenzingaJan 19 19:57
Wells Fargo Downgrades Sangamo, Cites Removal of Key Year-end Catalyst
Seeking AlphaNov 7, 2023 03:45
HC Wainwright & Co. Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $3
BenzingaNov 7, 2023 00:04
Wells Fargo Downgrades Sangamo Therapeutics to Equal-Weight, Announces $1 Price Target
BenzingaNov 6, 2023 21:21
Sangamo Therapeutics Analyst Ratings
BenzingaNov 6, 2023 21:19
RBC Capital Downgrades Sangamo as Biotech Moves to Save Cash
Seeking AlphaNov 4, 2023 03:32
RBC Capital Downgrades Sangamo Therapeutics to Sector Perform, Lowers Price Target to $2
BenzingaNov 3, 2023 18:20
Sangamo Therapeutics Analyst Ratings
BenzingaNov 3, 2023 18:19
Truist Securities Maintains Buy on Sangamo Therapeutics, Lowers Price Target to $7
BenzingaAug 15, 2023 22:37
Sangamo Therapeutics Analyst Ratings
BenzingaAug 15, 2023 22:36
H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)
TipRanksAug 14, 2023 20:36
No Data
No Data